Harbor Investment Advisory LLC Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Harbor Investment Advisory LLC lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 69.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 800 shares of the company’s stock after selling 1,843 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Moderna were worth $33,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of MRNA. MassMutual Private Wealth & Trust FSB raised its stake in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the last quarter. Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new stake in shares of Moderna during the third quarter worth approximately $80,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 7.3 %

MRNA opened at $38.50 on Thursday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a market cap of $14.82 billion, a P/E ratio of -6.62 and a beta of 1.60. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47. The business’s fifty day simple moving average is $40.52 and its 200 day simple moving average is $64.90.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.39) earnings per share. As a group, equities research analysts anticipate that Moderna, Inc. will post -9.27 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 over the last quarter. Insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on MRNA shares. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Jefferies Financial Group cut their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Monday, November 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $75.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.